• LAST PRICE
    15.1600
  • TODAY'S CHANGE (%)
    Trending Down-0.3500 (-2.2566%)
  • Bid / Lots
    13.0000/ 30
  • Ask / Lots
    17.1500/ 10
  • Open / Previous Close
    15.4600 / 15.5100
  • Day Range
    Low 15.0700
    High 15.5600
  • 52 Week Range
    Low 9.2600
    High 18.9583
  • Volume
    236,427
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 15.51
TimeVolumeACRS
09:32 ET64015.46
09:33 ET56615.49
09:35 ET20015.53
09:44 ET12315.415
09:48 ET45415.435
09:53 ET20815.48
10:02 ET53215.35
10:04 ET30015.405
10:13 ET10015.35
10:22 ET100015.47
10:24 ET30015.48
10:31 ET10015.535
10:33 ET20015.52
10:36 ET10015.46
10:40 ET10015.48
10:42 ET20015.52
10:44 ET10015.525
10:47 ET484115.41
10:49 ET50015.4
10:51 ET20015.38
10:54 ET20015.31
10:56 ET10015.34
10:58 ET68115.335
11:00 ET10015.28
11:02 ET40015.35
11:03 ET10015.4
11:12 ET10015.28
11:16 ET100215.33
11:18 ET30015.36
11:20 ET10015.3
11:21 ET10015.3
11:25 ET10015.285
11:34 ET30015.23
11:38 ET10015.25
11:41 ET10015.21
11:43 ET10015.237
11:45 ET122815.35
11:48 ET10015.26
11:54 ET10015.29
11:56 ET10015.34
11:57 ET10015.34
12:01 ET80015.28
12:03 ET20015.24
12:08 ET20015.24
12:10 ET90015.34
12:17 ET30015.27
12:21 ET30015.195
12:30 ET20015.15
12:32 ET50015.18
12:33 ET20015.2
12:35 ET30015.11
12:42 ET211615.24
12:44 ET30015.2
12:48 ET20015.15
12:57 ET50015.145
01:00 ET20015.13
01:02 ET10015.11
01:04 ET20015.11
01:08 ET120015.105
01:09 ET20015.12
01:11 ET20015.09
01:13 ET40015.12
01:18 ET20015.12
01:20 ET20015.1301
01:22 ET30015.115
01:24 ET90015.12
01:27 ET20015.13
01:31 ET10015.14
01:33 ET147915.2
01:36 ET20015.21
01:38 ET20015.195
01:40 ET10015.195
01:44 ET20015.19
01:45 ET69915.185
01:49 ET30015.2
01:51 ET10015.21
01:56 ET10015.18
01:58 ET10015.18
02:02 ET106315.18
02:03 ET10015.15
02:05 ET58315.14
02:07 ET40015.16
02:09 ET103315.16
02:16 ET10015.15
02:18 ET10015.155
02:21 ET50015.15
02:23 ET142015.17
02:25 ET10015.17
02:30 ET90015.19
02:32 ET20015.185
02:34 ET41215.2
02:36 ET10015.21
02:38 ET20015.19
02:39 ET110015.18
02:41 ET20015.17
02:43 ET50015.16
02:45 ET20015.165
02:48 ET30015.15
02:50 ET45015.165
02:52 ET70015.145
02:54 ET80015.145
02:56 ET305615.21
02:57 ET30015.18
02:59 ET60015.19
03:01 ET50015.22
03:03 ET40015.25
03:06 ET90015.23
03:08 ET50015.24
03:10 ET60015.185
03:12 ET30015.17
03:14 ET20015.2
03:15 ET10015.195
03:17 ET10015.2
03:19 ET40015.195
03:21 ET90015.155
03:24 ET167815.16
03:26 ET60015.16
03:28 ET50015.16
03:30 ET100015.14
03:32 ET133315.17
03:33 ET90015.15
03:35 ET929015.135
03:37 ET50015.12
03:39 ET144015.15
03:42 ET192915.14
03:44 ET80015.14
03:46 ET230015.16
03:48 ET107615.19
03:50 ET60015.19
03:51 ET83015.14
03:53 ET234815.18
03:55 ET182815.16
03:57 ET279615.17
04:00 ET923615.16
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACRS
Aclaris Therapeutics Inc
1.0B
-11.8x
---
United StatesNWBO
Northwest Biotherapeutics Inc
1.0B
14.2x
---
United StatesKURA
Kura Oncology Inc
1.0B
-7.4x
---
United StatesARQT
Arcutis Biotherapeutics Inc
1.0B
-2.9x
---
United StatesMORF
Morphic Holding Inc
1.0B
-17.1x
---
United StatesTGTX
TG Therapeutics Inc
1.1B
-4.2x
---
As of 2022-12-10

Company Information

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

Contact Information

Headquarters
640 Lee Rd Ste 200WAYNE, PA, United States 19087-5636
Phone
484-324-7933
Fax
302-655-5049

Executives

Lead Independent Director
Christopher Molineaux
President, Chief Executive Officer, Director
Douglas Manion
Chairman of the Board, Co-Founder
Neal Walker
Co-Founder, Chief Financial Officer, Secretary
Frank Ruffo
Chief Scientific Officer
Joseph Monahan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.0B
Revenue (TTM)
$23.5M
Shares Outstanding
66.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.56
EPS
$-1.29
Book Value
$3.22
P/E Ratio
-11.8x
Price/Sales (TTM)
43.0
Price/Cash Flow (TTM)
---
Operating Margin
-356.03%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.